Background: This study was conducted to determine the prevalence of hepatitis C virus antibody (anti-HCV), among a healthy university undergraduate population in south-western Nigeria. Materials and Methods: Relevant medical information of students who underwent the post-admission screening exercise for the year 2012, at the Ladoke Akintola University of Technology (LAUTECH), Health Center, Ogbomoso were extracted from the laboratory log book. All tests were done using rapid anti-HCV test kit by Health -Chem diagnostics, USA. A total of 1,572 students were included in the study. The mean age was 19.61 (± 2.75) years while the age range was 15-50 years. A total of 821 (52.20%), of the subjects were males while 751 (47.80%) were females. More than ninety nine percent (99.90%) of the subjects were aged 15-30 years, whereas those aged ≥31 years were comparatively few (0.60%). Results: Of the 1572 students, 6 tested positive, giving an overall prevalence of 0.40%. Three (0.37%) of the 821 male subjects tested positive while 3(0.40%) also of the 751 female subjects tested positive. Age-group 21-30 years had the highest prevalence of anti -HCV (0.50%), followed by agegroups ≤ 20 years with 0.30% prevalence. None of the subjects in age-groups 31-40 and ≥ 41 years tested positive. Conclusion: These observed differences were not statistically significant. The prevalence of Hepatitis C Virus is low among the young healthy undergraduate population in the south -western region of Nigeria.

No abstract

Purpose/Objective(s): In ATSHNSCC, direct comparisons between definitive treatment regimens are lacking. From 1998 to 2003, the chemoradiation therapy regimen employed was FHX, while from 2004 to 2009 it was CRT. To investigate whether one of these regimens was superior, we performed a review of patient outcomes that included overall survival (OS), disease-free survival (DFS), and long-term toxicity (LTT). Materials/Methods: The institutional review board approved this study, and the institution's tumor registry database was queried for all patients (pts) with (T3 or T4) ATSHNSCC. Medical records were examined for variables that included age, race, gender, and Eastern Cooperative Oncology Group performance status (PS). Tumor-specific data included subsite, stage, grade, treatment received, date of last follow-up, recurrence, and/or death. The following LTT's were assessed: difficulty speaking (DS), difficulty eating (DE), feeding tube placement (FT), tracheostomy (TO), mandibular osteoradionecrosis (MORN), mucocutaneous fistula (MCF), dry mouth (DM), and soft-tissue fibrosis (STF). Results: Three hundred and seventeen pts met eligibility and are included in this analysis. Median age is 57 years.